09/886,271

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	SEP 09	CA/CAplus records now contain indexing from 1907 to the present
NEWS 4	DEC 08	INPADOC: Legal Status data reloaded
NEWS 5	SEP 29	DISSABS now available on STN
NEWS 6	OCT 10	PCTFULL: Two new display fields added
NEWS 7	OCT 21	BIOSIS file reloaded and enhanced
NEWS 8	OCT 28	BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS 9	NOV 24	MSDS-CCOHS file reloaded
NEWS 10	DEC 08	CABA reloaded with left truncation
NEWS 11	DEC 08	IMS file names changed
NEWS 12	DEC 09	Experimental property data collected by CAS now available in REGISTRY
NEWS 13	DEC 09	STN Entry Date available for display in REGISTRY and CA/CAplus
NEWS 14	DEC 17	DGENE: Two new display fields added
NEWS 15	DEC 18	BIOTECHNO no longer updated
NEWS 16	DEC 19	CROPU no longer updated; subscriber discount no longer available
NEWS 17	DEC 22	Additional INPI reactions and pre-1907 documents added to CAS databases
NEWS 18	DEC 22	IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
NEWS 19	DEC 22	ABI-INFORM now available on STN
NEWS 20	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS 21	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAplus
NEWS 22	FEB 05	German (DE) application and patent publication number format changes
NEWS 23	MAR 03	MEDLINE and LMEDLINE reloaded
NEWS 24	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS 25	MAR 03	FRANCEPAT now available on STN

NEWS EXPRESS	MARCH 5 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 3 MARCH 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:10:45 ON 12 MAR 2004

=> file medline, biosis, biobusiness, wpids, fsta, jicst, embase, dgene, uspatful

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 13:11:13 ON 12 MAR 2004

FILE 'BIOSIS' ENTERED AT 13:11:13 ON 12 MAR 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'BIOBUSINESS' ENTERED AT 13:11:13 ON 12 MAR 2004
COPYRIGHT (C) 2004 Biological Abstracts, Inc. (BIOSIS)

FILE 'WPIDS' ENTERED AT 13:11:13 ON 12 MAR 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'FSTA' ENTERED AT 13:11:13 ON 12 MAR 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'JICST-EPLUS' ENTERED AT 13:11:13 ON 12 MAR 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'EMBASE' ENTERED AT 13:11:13 ON 12 MAR 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'DGENE' ENTERED AT 13:11:13 ON 12 MAR 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'USPATFULL' ENTERED AT 13:11:13 ON 12 MAR 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

=> s protein marker
L1 2389 PROTEIN MARKER

=> s obesity
L2 368909 OBESITY

=> s hypertension
L3 845017 HYPERTENSION

=> s diabetes
L4 1028410 DIABETES

=> s osteoarthritis
L5 270109 OSTEOARTHRITIS

=> s osteoporosis
L6 232226 OSTEOPOROSIS

=> s l1 an dl2
MISSING OPERATOR L1 AN
The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s l1 and l2
L7 218 L1 AND L2

```
=> s l1 () l3
L8              0 L1 (W) L3

=> s l1 and l3
L9            267 L1 AND L3

=> s l1 and l4
L10           308 L1 AND L4

=> s l1 and l5
L11           226 L1 AND L5

=> s l1 and l6
L12           209 L1 AND L6

=> s l7 and non-genetic
L13             8 L7 AND NON-GENETIC

=> d l13 ti abs ibib tot
```

L13 ANSWER 1 OF 8 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN

TI New **non-genetic** based protein disease markers for **obesity**, osteoporosis, diabetes, osteoathritis and hypertension, useful in diagnosis and monitoring of treatment for these diseases and to screen for therapeutic compounds.

AN 2002-362307 [39] WPIDS

AB WO 200222165 A UPAB: 20020621

NOVELTY - **Non-genetic** based protein disease markers for **obesity**, osteoporosis, diabetes, osteoathritis and hypertension, are new.

DETAILED DESCRIPTION - **Non-genetic** based protein disease markers for **obesity**, osteoporosis, diabetes, osteoathritis and hypertension, are new, where markers for **obesity** (n=34), osteoporosis (n=20), diabetes (n=9), osteoathritis (n=1) and hypertension (n=9) are listed in the specification.

INDEPENDENT CLAIMS are also included for the following:

(1) determining a disease state of a subject suspected of having **obesity**, osteoporosis, diabetes, osteoathritis or hypertension comprising:

(a) obtaining a sample containing protein;

(b) measuring levels of protein markers of the disease state, where the markers are given in the specification; and

(c) comparing with levels in controls from disease-free subjects/control standards;

(2) binding reagents specific for the proteins, optionally bound to a detectable label;

(3) a standardized two-dimensional electrophoretic protein distribution from a sample (optionally human serum) from a subject having **obesity**, osteoporosis, diabetes, osteoathritis or hypertension (and optionally being treated with pharmaceuticals);

(4) protein markers comprising a composition of two or more proteins which individually do not have significantly different levels between disease/control samples in a method as in (1), but produce a combined value which is significantly different, and methods and binding reagents as in (1) and (2) relating to the markers;

(5) protein submarkers not altered statistically significantly in the method as in (1) but altered in tandem/opposite in level and direction to protein markers, and methods and binding reagents as in (1) and (2) relating to the markers;

(6) generating an index marker for a particular physiological state comprising:

(a) determining protein markers that differ between samples from a subject with a disease state and a control sample;

(b) selecting two or more of the markers;

(c) combining the values for the markers and determining where the combination of values is altered in a manner of greater statistical significance;

(7) index markers comprising two or more protein markers determined by (6);

(8) cloning a gene encoding a **protein marker** comprising:

(a) determining a partial amino acid sequence of the protein;

(b) deducing a nucleotide sequence for a gene encoding the protein; and

(c) isolating or synthesizing a gene encoding the nucleotide sequence; and

(9) polynucleotides encoding the proteins, and antisense sequences inhibiting gene expression.

ACTIVITY - Anorectic; osteopathic; antidiabetic; antiarthritic; hypotensive. No biological data is given.

MECHANISM OF ACTION - None given.

USE - The markers and a new method are useful to diagnose **obesity**, osteoporosis, diabetes, osteoathritis or hypertension in individuals. Marker levels may also be used to determine disease severity. The markers and method can also be used to monitor the efficacy of therapy for the conditions, by comparing marker levels between samples from a subject taken at different times. The markers identified may also be drug development targets for the diseases. The protein markers can be used to screen compounds for biological activity against the diseases, which may be included with a carrier in pharmaceutical compositions useful to treat the disease states. The markers are useful to screen candidate compounds for detection of or therapeutic activity against disease states, and to identify biological pathways involved in disease states. They are also useful to identify synergistic agents which may be included in pharmaceutical compositions (all claimed).

Dwg.0/10

ACCESSION NUMBER: 2002-362307 [39] WPIDS

DOC. NO. CPI: C2002-102544

TITLE: New **non-genetic** based protein disease markers for **obesity**, osteoporosis, diabetes, osteoathritis and hypertension, useful in diagnosis and monitoring of treatment for these diseases and to screen for therapeutic compounds.

DERWENT CLASS: B04 D16

INVENTOR(S): ANDERSON, N L; MYERS, T G; PIEPER, R; STEINER, S; TAYLOR, J; MYERS, T; REMBERT, P

PATENT ASSIGNEE(S): (ANDE-I) ANDERSON N L; (MYER-I) MYERS T G; (PIEP-I) PIEPER R; (STEI-I) STEINER S; (TAYL-I) TAYLOR J; (LARG-N) LARGE SCALE PROTEOMICS CORP

COUNTRY COUNT: 97

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2002022165	A1	20020321	(200239)*	EN	63
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW					
US 2002072492	A1	20020613	(200243)		
AU 2001088973	A	20020326	(200251)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE

WO 2002022165 A1		WO 2001-US28268	20010912
US 2002072492 A1	CIP of	US 2000-660242	20000912
		US 2001-886271	20010622
AU 2001088973 A		AU 2001-88973	20010912

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2001088973 A	Based on	WO 2002022165

PRIORITY APPLN. INFO: US 2001-886271 20010622; US 2000-660242 20000912

L13 ANSWER 2 OF 8 USPATFULL on STN

TI Novel 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 molecules and uses therefor

AB The invention provides isolated nucleic acids molecules, designated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 gene has been introduced or disrupted. The invention still further provides isolated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 proteins, fusion proteins, antigenic peptides and anti-25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2004:12981 USPATFULL
TITLE:	Novel 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 molecules and uses therefor
INVENTOR(S):	Curtis, Rory A. J., Ashland, MA, UNITED STATES Logan, Thomas Joseph, Springfield, PA, UNITED STATES Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES Meyers, Rachel E., Newton, MA, UNITED STATES Williamson, Mark J., Saugus, MA, UNITED STATES Rudolph-Owen, Laura A., Medford, MA, UNITED STATES Chun, Miyoung, Belmont, MA, UNITED STATES Tsai, Fong-Ying, Newton, MA, UNITED STATES
PATENT ASSIGNEE(S):	Millennium Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004009501	A1	20040115	
APPLICATION INFO.:	US 2003-377072	A1	20030227	(10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-895860, filed on 29 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2000-723806, filed on 28 Nov 2000, PENDING Continuation-in-part of Ser. No. US 2001-843297, filed on 25 Apr 2001, GRANTED, Pat. No. US 6569667 Continuation-in-part of Ser. No. US 2001-861801, filed on 21 May 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-816494, filed on 23 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2001-888911, filed on 25 Jun 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-908664, filed on 17 Jul 2001, ABANDONED

Continuation-in-part of Ser. No. US 2001-935291, filed on 21 Aug 2001, ABANDONED

PRIORITY INFORMATION:	NUMBER	DATE
	US 2000-215370P	20000629 (60)
	US 2000-187455P	20000307 (60)
	US 2000-199801P	20000426 (60)
	US 2000-205508P	20000519 (60)
	US 2000-213688P	20000623 (60)
	US 2000-218675P	20000717 (60)
	US 2000-250932P	20001130 (60)
	US 2000-226504P	20000821 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Jean M. Silveri, 75 Sidney Street, Cambridge, MA, 02139
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
LINE COUNT: 16123

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 3 OF 8 USPATFULL on STN

TI Novel 38594, 57312, 53659, 57250, 63760, 49938, 32146, 57259, 67118, 67067, 62092, 8099, 46455, 54414, 53763, 67076, 67102, 44181, 67084FL, 67084ALT, FBH58295FL, 57255, and 57255alt molecules and uses therefor

AB The invention provides isolated nucleic acids molecules, designated 38594, 57312, 53659, 57250, 63760, 49938, 32146, 57259, 67118, 67067, 62092, 8099, 46455, 54414, 53763, 67076, 67102, 44181, 67084FL, 67084ALT, FBH58295FL, 57255, and 57255alt nucleic acid molecules, which encode transporter molecules, including sugar transporters, organic anion transporters, amino acid transporters, and phospholipid transporters. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 38594, 57312, 53659, 57250, 63760, 49938, 32146, 57259, 67118, 67067, 62092, 8099, 46455, 54414, 53763, 67076, 67102, 44181, 67084FL, 67084ALT, FBH58295FL, 57255, and 57255alt nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a 38594, 57312, 53659, 57250, 63760, 49938, 32146, 57259, 67118, 67067, 62092, 8099, 46455, 54414, 53763, 67076, 67102, 44181, 67084FL, 67084ALT, FBH58295FL, 57255, and 57255alt gene has been introduced or disrupted. The invention still further provides isolated 38594, 57312, 53659, 57250, 63760, 49938, 32146, 57259, 67118, 67067, 62092, 8099, 46455, 54414, 53763, 67076, 67102, 44181, 67084FL, 67084ALT, FBH58295FL, 57255, and 57255alt polypeptides, fusion polypeptides, antigenic peptides and anti-38594, 57312, 53659, 57250, 63760, 49938, 32146, 57259, 67118, 67067, 62092, 8099, 46455, 54414, 53763, 67076, 67102, 44181, 67084FL, 67084ALT, FBH58295FL, 57255, and 57255alt antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:207317 USPATFULL
TITLE: Novel 38594, 57312, 53659, 57250, 63760, 49938, 32146, 57259, 67118, 67067, 62092, 8099, 46455, 54414, 53763, 67076, 67102, 44181, 67084FL, 67084ALT, FBH58295FL, 57255, and 57255alt molecules and uses therefor
INVENTOR(S): Curtis, Rory A.J., Framingham, MA, UNITED STATES
Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
Meyers, Rachel E., Newton, MA, UNITED STATES
PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., Cambridge, MA (U.S. corporation)

	NUMBER	KIND	DATE

PATENT INFORMATION:	US 2003143675	A1	20030731
APPLICATION INFO.:	US 2002-154419	A1	20020522 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-858194, filed on 14 May 2001, PENDING Continuation-in-part of Ser. No. US 2001-895811, filed on 29 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2001-919781, filed on 31 Jul 2001, PENDING Continuation-in-part of Ser. No. US 2001-957664, filed on 19 Sep 2001, PENDING Continuation-in-part of Ser. No. US 2001-964295, filed on 25 Sep 2001, PENDING Continuation-in-part of Ser. No. US 2001-972724, filed on 5 Oct 2001, PENDING Continuation-in-part of Ser. No. US 2001-2769, filed on 14 Nov 2001, PENDING Continuation-in-part of Ser. No. US 2001-24623, filed on 17 Dec 2001, PENDING Continuation-in-part of Ser. No. US 2002-55025, filed on 22 Jan 2002, PENDING

PRIORITY INFORMATION:	NUMBER	DATE
	US 2000-204211P	20000512 (60)
	US 2000-215376P	20000629 (60)
	US 2000-221769P	20000731 (60)
	US 2000-233790P	20000919 (60)
	US 2000-235107P	20000925 (60)
	US 2000-238336P	20001005 (60)
	US 2000-248364P	20001114 (60)
	US 2000-248878P	20001115 (60)
	US 2000-256240P	20001215 (60)
	US 2000-256588P	20001218 (60)
	US 2000-258028P	20001221 (60)
	US 2001-263169P	20010122 (60)
	US 2001-263169P	20010122 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Intellectual Property Group, MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street, Cambridge, MA, 02139
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 252 Drawing Page(s)
LINE COUNT: 45817
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 4 OF 8 USPATFULL on STN

TI 68723, sodium/glucose cotransporter family members and uses therefor

AB The invention provides isolated nucleic acids molecules, designated 68723 nucleic acid molecules, which encode novel sodium/glucose cotransporter family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 68723 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 68723 gene has been introduced or disrupted. The invention still further provides isolated 68723 proteins, fusion proteins, antigenic peptides and anti-68723 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:78533 USPATFULL
TITLE:	68723, sodium/glucose cotransporter family members and uses therefor
INVENTOR(S):	Curtis, Rory A.J., Framingham, MA, UNITED STATES Chen, Hong, Newton, MA, UNITED STATES
PATENT ASSIGNEE(S):	Millennium Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003054453	A1	20030320	
APPLICATION INFO.:	US 2002-119988	A1	20020410	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-282764P	20010410 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Jean M. Silveri, MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street, Cambridge, MA, 02139
NUMBER OF CLAIMS: 43
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 6315
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 5 OF 8 USPATFULL on STN
TI 18607, a novel human calcium channel
AB The invention provides isolated nucleic acids molecules, designated TLCC nucleic acid molecules, which encode novel TRP-like calcium channel molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing TLCC nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a TLCC gene has been introduced or disrupted. The invention still further provides isolated TLCC proteins, fusion proteins, antigenic peptides and anti-TLCC antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:258807 USPATFULL
TITLE: 18607, a novel human calcium channel
INVENTOR(S): Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
Curtis, Rory A.J., Southborough, MA, UNITED STATES
Lora, Jose M., Arlington, MA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002142377	A1	20021003	
APPLICATION INFO.:	US 2001-789481	A1	20010220	(9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-634669, filed on 8 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-583373, filed on 31 May 2000, PENDING Continuation-in-part of Ser. No. US 2000-510706, filed on 22 Feb 2000, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109
NUMBER OF CLAIMS: 44
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 26 Drawing Page(s)
LINE COUNT: 5230
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 6 OF 8 USPATFULL on STN
TI 25869, a novel human carboxylesterase and uses thereof
AB The invention provides isolated nucleic acid molecules, designated COE-1 nucleic acid molecules, which encode novel carboxylesterase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing COE-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and

nonhuman transgenic animals in which a COE-1 gene has been introduced or disrupted. The invention still further provides isolated COE-1 proteins, fusion proteins, antigenic peptides and anti-COE-1 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:148643 USPATFULL
TITLE: 25869, a novel human carboxylesterase and uses thereof
INVENTOR(S): Curtis, Rory A.J., Southborough, MA, UNITED STATES
Logan, Thomas Joseph, Needham, MA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002076786	A1	20020620	
APPLICATION INFO.:	US 2001-895860	A1	20010629	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-215370P	20000629 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109
NUMBER OF CLAIMS: 32
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Page(s)
LINE COUNT: 5139
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 7 OF 8 USPATFULL on STN
TI **Non-genetic** based protein disease markers
AB Protein disease markers for **obesity**, osteoporosis, diabetes, osteoarthritis and hypertension are disclosed. These markers are not inherited or of genetic origin as they were not found in identical twins of the affected individual. Methods and uses for diagnostic, therapeutic and drug discovery are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:141506 USPATFULL
TITLE: **Non-genetic** based protein disease markers
INVENTOR(S): Myers, Timothy G., Kensington, MD, UNITED STATES
Pieper, Rembert, Washington, DC, UNITED STATES
Taylor, John, JR., Clayton, NC, UNITED STATES
Steiner, Sandra, Gaithersburg, MD, UNITED STATES
Anderson, N. Leigh, Washington, DC, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002072492	A1	20020613	
APPLICATION INFO.:	US 2001-886271	A1	20010622	(9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-660242, filed on 12 Sep 2000, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Dean H. Nakamura, Roylance Abrams Berdo & Goodman, 1300 19th Street, N.W., Washington, DC, 20036
NUMBER OF CLAIMS: 55
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 1425
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 8 OF 8 USPATFULL on STN

TI Methods and compositions for elucidating relative protein expression levels in cells

AB The present invention relates generally to methods and compositions for the identification of differential protein expression patterns and concomitantly the active genetic regions that are directly or indirectly involved in different tissue types, disease states, or other cellular differences desirable for diagnosis or for targets for drug therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:188396 USPATFULL

TITLE: Methods and compositions for elucidating relative protein expression levels in cells

INVENTOR(S): Link, Charles J., Des Moines, IA, United States
Seregina, Tatiana, Ames, IA, United States
Vahanian, Nicholas N., Ames, IA, United States
Higginbotham, James N., Ames, IA, United States
Ramsey, W. Jay, Ames, IA, United States
Powers, Bradley J., Ames, IA, United States
Shulka, Sachet A., Ames, IA, United States
Young, Won Bin, Ames, IA, United States

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2001034028	A1	20011025	
APPLICATION INFO.:	US 2001-811842	A1	20010319	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-190678P	20000320	(60)
	US 2000-198722P	20000420	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ZARLEY MCKEE THOMTE VOORHEES & SEASE PLC, SUITE 3200, 801 GRAND AVENUE, DES MOINES, IA, 50309-2721
NUMBER OF CLAIMS: 52
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Page(s)
LINE COUNT: 2290
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 13:10:45 ON 12 MAR 2004)

FILE 'MEDLINE, BIOSIS, BIOBUSINESS, WPIDS, FSTA, JICST-EPLUS, EMBASE, DGENE, USPATFULL' ENTERED AT 13:11:13 ON 12 MAR 2004

L1	2389	S	PROTEIN MARKER
L2	368909	S	OBESITY
L3	845017	S	HYPERTENSION
L4	1028410	S	DIABETES
L5	270109	S	OSTEOARTHRITIS
L6	232226	S	OSTEOPOROSIS
L7	218	S	L1 AND L2
L8	0	S	L1 () L3
L9	267	S	L1 AND L3
L10	308	S	L1 AND L4
L11	226	S	L1 AND L5
L12	209	S	L1 AND L6
L13	8	S	L7 AND NON-GENETIC

=> s l9 and NON-GENETIC
1 FILES SEARCHED...

L14	9	L9	AND NON-GENETIC

=> d l14 ti abs ibib tot

L14 ANSWER 1 OF 9 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
TI New **non-genetic** based protein disease markers for obesity, osteoporosis, diabetes, osteoathritis and **hypertension**, useful in diagnosis and monitoring of treatment for these diseases and to screen for therapeutic compounds.
AN 2002-362307 [39] WPIDS
AB WO 200222165 A UPAB: 20020621
NOVELTY - **Non-genetic** based protein disease markers for obesity, osteoporosis, diabetes, osteoathritis and **hypertension**, are new.

DETAILED DESCRIPTION - **Non-genetic** based protein disease markers for obesity, osteoporosis, diabetes, osteoathritis and **hypertension**, are new, where markers for obesity (n=34), osteoporosis (n=20), diabetes (n=9), osteoathritis (n=1) and **hypertension** (n=9) are listed in the specification.

INDEPENDENT CLAIMS are also included for the following:

(1) determining a disease state of a subject suspected of having obesity, osteoporosis, diabetes, osteoathritis or **hypertension** comprising:

(a) obtaining a sample containing protein;

(b) measuring levels of protein markers of the disease state, where the markers are given in the specification; and

(c) comparing with levels in controls from disease-free subjects/control standards;

(2) binding reagents specific for the proteins, optionally bound to a detectable label;

(3) a standardized two-dimensional electrophoretic protein distribution from a sample (optionally human serum) from a subject having obesity, osteoporosis, diabetes, osteoathritis or **hypertension** (and optionally being treated with pharmaceuticals);

(4) protein markers comprising a composition of two or more proteins which individually do not have significantly different levels between disease/control samples in a method as in (1), but produce a combined value which is significantly different, and methods and binding reagents as in (1) and (2) relating to the markers;

(5) protein submarkers not altered statistically significantly in the method as in (1) but altered in tandem/opposite in level and direction to protein markers, and methods and binding reagents as in (1) and (2) relating to the markers;

(6) generating an index marker for a particular physiological state comprising:

(a) determining protein markers that differ between samples from a subject with a disease state and a control sample;

(b) selecting two or more of the markers;

(c) combining the values for the markers and determining where the combination of values is altered in a manner of greater statistical significance;

(7) index markers comprising two or more protein markers determined by (6);

(8) cloning a gene encoding a **protein marker** comprising:

(a) determining a partial amino acid sequence of the protein;

(b) deducing a nucleotide sequence for a gene encoding the protein; and

(c) isolating or synthesizing a gene encoding the nucleotide sequence; and

(9) polynucleotides encoding the proteins, and antisense sequences inhibiting gene expression.

ACTIVITY - Anorectic; osteopathic; antidiabetic; antiarthritic; hypotensive. No biological data is given.

MECHANISM OF ACTION - None given.

USE - The markers and a new method are useful to diagnose obesity, osteoporosis, diabetes, osteoathritis or **hypertension** in individuals. Marker levels may also be used to determine disease severity. The markers and method can also be used to monitor the efficacy of therapy for the conditions, by comparing marker levels between samples from a subject taken at different times. The markers identified may also be drug development targets for the diseases. The protein markers can be used to screen compounds for biological activity against the diseases, which may be included with a carrier in pharmaceutical compositions useful to treat the disease states. The markers are useful to screen candidate compounds for detection of or therapeutic activity against disease states, and to identify biological pathways involved in disease states. They are also useful to identify synergistic agents which may be included in pharmaceutical compositions (all claimed).

Dwg.0/10

ACCESSION NUMBER: 2002-362307 [39] WPIDS
DOC. NO. CPI: C2002-102544
TITLE: New **non-genetic** based protein disease markers for obesity, osteoporosis, diabetes, osteoathritis and **hypertension**, useful in diagnosis and monitoring of treatment for these diseases and to screen for therapeutic compounds.
DERWENT CLASS: B04 D16
INVENTOR(S): ANDERSON, N L; MYERS, T G; PIEPER, R; STEINER, S; TAYLOR, J; MYERS, T; REMBERT, P
PATENT ASSIGNEE(S): (ANDE-I) ANDERSON N L; (MYER-I) MYERS T G; (PIEP-I) PIEPER R; (STEI-I) STEINER S; (TAYL-I) TAYLOR J; (LARG-N) LARGE SCALE PROTEOMICS CORP
COUNTRY COUNT: 97
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2002022165	A1	20020321	(200239)*	EN	63
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW					
US 2002072492	A1	20020613	(200243)		
AU 2001088973	A	20020326	(200251)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2002022165	A1	WO 2001-US28268	20010912
US 2002072492	A1 CIP of	US 2000-660242	20000912
		US 2001-886271	20010622
AU 2001088973	A	AU 2001-88973	20010912

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2001088973	A Based on	WO 2002022165

PRIORITY APPLN. INFO: US 2001-886271 20010622; US 2000-660242 20000912

L14 ANSWER 2 OF 9 USPATFULL on STN
TI Novel 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 molecules and uses therefor

AB The invention provides isolated nucleic acids molecules, designated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 gene has been introduced or disrupted. The invention still further provides isolated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 proteins, fusion proteins, antigenic peptides and anti-25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:12981 USPATFULL

TITLE: Novel 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 molecules and uses therefor

INVENTOR(S): Curtis, Rory A. J., Ashland, MA, UNITED STATES
Logan, Thomas Joseph, Springfield, PA, UNITED STATES
Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
Meyers, Rachel E., Newton, MA, UNITED STATES
Williamson, Mark J., Saugus, MA, UNITED STATES
Rudolph-Owen, Laura A., Medford, MA, UNITED STATES
Chun, Miyoung, Belmont, MA, UNITED STATES
Tsai, Fong-Ying, Newton, MA, UNITED STATES

PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004009501	A1	20040115	
APPLICATION INFO.:	US 2003-377072	A1	20030227	(10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-895860, filed on 29 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2000-723806, filed on 28 Nov 2000, PENDING Continuation-in-part of Ser. No. US 2001-843297, filed on 25 Apr 2001, GRANTED, Pat. No. US 6569667 Continuation-in-part of Ser. No. US 2001-861801, filed on 21 May 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-816494, filed on 23 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2001-888911, filed on 25 Jun 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-908664, filed on 17 Jul 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-935291, filed on 21 Aug 2001, ABANDONED

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-215370P	20000629	(60)
	US 2000-187455P	20000307	(60)
	US 2000-199801P	20000426	(60)
	US 2000-205508P	20000519	(60)
	US 2000-213688P	20000623	(60)
	US 2000-218675P	20000717	(60)
	US 2000-250932P	20001130	(60)
	US 2000-226504P	20000821	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Jean M. Silveri, 75 Sidney Street, Cambridge, MA, 02139

NUMBER OF CLAIMS: 19

EXEMPLARY CLAIM: 1
LINE COUNT: 16123
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 3 OF 9 USPATFULL on STN

TI Novel 27875, 22025 ,27420, 17906, 16319, 55092 and 10218 molecules and uses therefor

AB The invention provides isolated nucleic acids molecules, designated 27875, 22025, 27420, 16319, 55092 and 10218 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27875, 22025, 27420, 16319, 55092 and 10218 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 27875, 22025, 27420, 16319, 55092 and 10218 gene has been introduced or disrupted. The invention still further provides isolated 27875, 22025, 27420, 17906, 16319, 55092 or 10218 proteins, fusion proteins, antigenic peptides and anti-27875, 22025, 27420, 17906, 16319, 55092 or 10218 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:7776 USPATFULL
TITLE: Novel 27875, 22025 ,27420, 17906, 16319, 55092 and 10218 molecules and uses therefor

INVENTOR(S): Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
White, David, Braintree, MA, UNITED STATES
Robison, Keith E., Wilmington, MA, UNITED STATES
MacBeth, Kyle J., Boston, MA, UNITED STATES
Carroll, Joseph M., Cambridge, MA, UNITED STATES
Cook, William James, Hanover, NH, UNITED STATES
Meyers, Rachel E., Newton, MA, UNITED STATES
Chun, Miyoung, Belmont, MA, UNITED STATES
Williamson, Mark J., Saugus, MA, UNITED STATES
PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004006016	A1	20040108	
APPLICATION INFO.:	US 2003-386414	A1	20030311	(10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-426282, filed on 25 Oct 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-668266, filed on 22 Sep 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-330970, filed on 11 Jun 1999, GRANTED, Pat. No. US 6146876 Continuation-in-part of Ser. No. US 2000-724599, filed on 28 Nov 2000, PENDING Continuation-in-part of Ser. No. US 2001-860193, filed on 16 May 2001, PENDING Continuation-in-part of Ser. No. US 2000-571689, filed on 16 May 2000, ABANDONED Continuation-in-part of Ser. No. US 2002-283023, filed on 29 Oct 2002, PENDING Continuation-in-part of Ser. No. US 2001-10943, filed on 6 Dec 2001, PENDING Continuation-in-part of Ser. No. US 2001-833082, filed on 10 Apr 2001, ABANDONED

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2001-335044P	20011031	(60)
	US 2000-254037P	20001207	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
NUMBER OF CLAIMS: 18

EXEMPLARY CLAIM: 1
LINE COUNT: 25349
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 4 OF 9 USPATFULL on STN

TI Novel 38594, 57312, 53659, 57250, 63760, 49938, 32146, 57259, 67118, 67067, 62092, 8099, 46455, 54414, 53763, 67076, 67102, 44181, 67084FL, 67084ALT, FBH58295FL, 57255, and 57255alt molecules and uses therefor

AB The invention provides isolated nucleic acids molecules, designated 38594, 57312, 53659, 57250, 63760, 49938, 32146, 57259, 67118, 67067, 62092, 8099, 46455, 54414, 53763, 67076, 67102, 44181, 67084FL, 67084ALT, FBH58295FL, 57255, and 57255alt nucleic acid molecules, which encode transporter molecules, including sugar transporters, organic anion transporters, amino acid transporters, and phospholipid transporters. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 38594, 57312, 53659, 57250, 63760, 49938, 32146, 57259, 67118, 67067, 62092, 8099, 46455, 54414, 53763, 67076, 67102, 44181, 67084FL, 67084ALT, FBH58295FL, 57255, and 57255alt nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a 38594, 57312, 53659, 57250, 63760, 49938, 32146, 57259, 67118, 67067, 62092, 8099, 46455, 54414, 53763, 67076, 67102, 44181, 67084FL, 67084ALT, FBH58295FL, 57255, and 57255alt gene has been introduced or disrupted. The invention still further provides isolated 38594, 57312, 53659, 57250, 63760, 49938, 32146, 57259, 67118, 67067, 62092, 8099, 46455, 54414, 53763, 67076, 67102, 44181, 67084FL, 67084ALT, FBH58295FL, 57255, and 57255alt polypeptides, fusion polypeptides, antigenic peptides and anti-38594, 57312, 53659, 57250, 63760, 49938, 32146, 57259, 67118, 67067, 62092, 8099, 46455, 54414, 53763, 67076, 67102, 44181, 67084FL, 67084ALT, FBH58295FL, 57255, and 57255alt antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:207317 USPATFULL

TITLE: Novel 38594, 57312, 53659, 57250, 63760, 49938, 32146, 57259, 67118, 67067, 62092, 8099, 46455, 54414, 53763, 67076, 67102, 44181, 67084FL, 67084ALT, FBH58295FL, 57255, and 57255alt molecules and uses therefor

INVENTOR(S): Curtis, Rory A.J., Framingham, MA, UNITED STATES
Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
Meyers, Rachel E., Newton, MA, UNITED STATES

PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., Cambridge, MA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003143675	A1	20030731
APPLICATION INFO.:	US 2002-154419	A1	20020522 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-858194, filed on 14 May 2001, PENDING Continuation-in-part of Ser. No. US 2001-895811, filed on 29 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2001-919781, filed on 31 Jul 2001, PENDING Continuation-in-part of Ser. No. US 2001-957664, filed on 19 Sep 2001, PENDING Continuation-in-part of Ser. No. US 2001-964295, filed on 25 Sep 2001, PENDING Continuation-in-part of Ser. No. US 2001-972724, filed on 5 Oct 2001, PENDING Continuation-in-part of Ser. No. US 2001-2769, filed on 14 Nov 2001, PENDING Continuation-in-part of Ser. No. US 2001-24623, filed on 17 Dec 2001, PENDING Continuation-in-part of Ser. No. US 2002-55025, filed on 22 Jan 2002, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-204211P	20000512 (60)
	US 2000-215376P	20000629 (60)
	US 2000-221769P	20000731 (60)
	US 2000-233790P	20000919 (60)
	US 2000-235107P	20000925 (60)
	US 2000-238336P	20001005 (60)
	US 2000-248364P	20001114 (60)
	US 2000-248878P	20001115 (60)
	US 2000-256240P	20001215 (60)
	US 2000-256588P	20001218 (60)
	US 2000-258028P	20001221 (60)
	US 2001-263169P	20010122 (60)
	US 2001-263169P	20010122 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Intellectual Property Group, MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street, Cambridge, MA, 02139
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 252 Drawing Page(s)
LINE COUNT: 45817
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 5 OF 9 USPATFULL on STN
TI 68723, sodium/glucose cotransporter family members and uses therefor
AB The invention provides isolated nucleic acids molecules, designated 68723 nucleic acid molecules, which encode novel sodium/glucose cotransporter family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 68723 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 68723 gene has been introduced or disrupted. The invention still further provides isolated 68723 proteins, fusion proteins, antigenic peptides and anti-68723 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:78533 USPATFULL
TITLE: 68723, sodium/glucose cotransporter family members and uses therefor
INVENTOR(S): Curtis, Rory A.J., Framingham, MA, UNITED STATES
Chen, Hong, Newton, MA, UNITED STATES
PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003054453	A1	20030320	
APPLICATION INFO.:	US 2002-119988	A1	20020410	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-282764P	20010410 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Jean M. Silveri, MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street, Cambridge, MA, 02139
NUMBER OF CLAIMS: 43
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 6315

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 6 OF 9 USPATFULL on STN
TI 18607, a novel human calcium channel
AB The invention provides isolated nucleic acids molecules, designated TLCC nucleic acid molecules, which encode novel TRP-like calcium channel molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing TLCC nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a TLCC gene has been introduced or disrupted. The invention still further provides isolated TLCC proteins, fusion proteins, antigenic peptides and anti-TLCC antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2002:258807 USPATFULL
TITLE:	18607, a novel human calcium channel
INVENTOR(S):	Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES Curtis, Rory A.J., Southborough, MA, UNITED STATES Lora, Jose M., Arlington, MA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002142377	A1	20021003	
APPLICATION INFO.:	US 2001-789481	A1	20010220	(9)

RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-634669, filed on 8 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-583373, filed on 31 May 2000, PENDING Continuation-in-part of Ser. No. US 2000-510706, filed on 22 Feb 2000, PENDING
DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109
NUMBER OF CLAIMS:	44
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	26 Drawing Page(s)
LINE COUNT:	5230

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 7 OF 9 USPATFULL on STN
TI 25869, a novel human carboxylesterase and uses thereof
AB The invention provides isolated nucleic acid molecules, designated COE-1 nucleic acid molecules, which encode novel carboxylesterase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing COE-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a COE-1 gene has been introduced or disrupted. The invention still further provides isolated COE-1 proteins, fusion proteins, antigenic peptides and anti-COE-1 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2002:148643 USPATFULL
TITLE:	25869, a novel human carboxylesterase and uses thereof
INVENTOR(S):	Curtis, Rory A.J., Southborough, MA, UNITED STATES Logan, Thomas Joseph, Needham, MA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002076786	A1	20020620	
APPLICATION INFO.:	US 2001-895860	A1	20010629	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-215370P	20000629 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109
NUMBER OF CLAIMS: 32
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Page(s)
LINE COUNT: 5139
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 8 OF 9 USPATFULL on STN
TI **Non-genetic** based protein disease markers
AB Protein disease markers for obesity, osteoporosis, diabetes, osteoarthritis and **hypertension** are disclosed. These markers are not inherited or of genetic origin as they were not found in identical twins of the affected individual. Methods and uses for diagnostic, therapeutic and drug discovery are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:141506 USPATFULL
TITLE: **Non-genetic** based protein disease markers
INVENTOR(S): Myers, Timothy G., Kensington, MD, UNITED STATES
Pieper, Rembert, Washington, DC, UNITED STATES
Taylor, John, JR., Clayton, NC, UNITED STATES
Steiner, Sandra, Gaithersburg, MD, UNITED STATES
Anderson, N. Leigh, Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002072492	A1	20020613
APPLICATION INFO.:	US 2001-886271	A1	20010622 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-660242, filed on 12 Sep 2000, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Dean H. Nakamura, Roylance Abrams Berdo & Goodman, 1300 19th Street, N.W., Washington, DC, 20036
NUMBER OF CLAIMS: 55
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 1425
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 9 OF 9 USPATFULL on STN
TI Methods and compositions for elucidating relative protein expression levels in cells
AB The present invention relates generally to methods and compositions for the identification of differential protein expression patterns and concomitantly the active genetic regions that are directly or indirectly involved in different tissue types, disease states, or other cellular differences desirable for diagnosis or for targets for drug therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2001:188396 USPATFULL
TITLE: Methods and compositions for elucidating relative protein expression levels in cells
INVENTOR(S): Link, Charles J., Des Moines, IA, United States
Seregina, Tatiana, Ames, IA, United States
Vahanian, Nicholas N., Ames, IA, United States
Higginbotham, James N., Ames, IA, United States
Ramsey, W. Jay, Ames, IA, United States

Powers, Bradley J., Ames, IA, United States
Shulka, Sachet A., Ames, IA, United States
Young, Won Bin, Ames, IA, United States

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2001034028	A1	20011025	
APPLICATION INFO.:	US 2001-811842	A1	20010319	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-190678P	20000320	(60)
	US 2000-198722P	20000420	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ZARLEY MCKEE THOMTE VOORHEES & SEASE PLC, SUITE 3200, 801 GRAND AVENUE, DES MOINES, IA, 50309-2721
NUMBER OF CLAIMS: 52
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Page(s)
LINE COUNT: 2290
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 13:10:45 ON 12 MAR 2004)

FILE 'MEDLINE, BIOSIS, BIOBUSINESS, WPIDS, FSTA, JICST-EPLUS, EMBASE, DGENE, USPATFULL' ENTERED AT 13:11:13 ON 12 MAR 2004

```
L1          2389 S PROTEIN MARKER
L2        368909 S OBESITY
L3        845017 S HYPERTENSION
L4       1028410 S DIABETES
L5        270109 S OSTEOARTHRITIS
L6        232226 S OSTEOPOROSIS
L7           218 S L1 AND L2
L8             0 S L1 () L3
L9           267 S L1 AND L3
L10          308 S L1 AND L4
L11          226 S L1 AND L5
L12          209 S L1 AND L6
L13            8 S L7 AND NON-GENETIC
L14            9 S L9 AND NON-GENETIC
```

```
=> s l10 and NON-GENETIC
L15             9 L10 AND NON-GENETIC
```

=> d l15 ti abs ibib tot

L15 ANSWER 1 OF 9 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
TI New **non-genetic** based protein disease markers for obesity, osteoporosis, **diabetes**, osteoathritis and hypertension, useful in diagnosis and monitoring of treatment for these diseases and to screen for therapeutic compounds.
AN 2002-362307 [39] WPIDS
AB WO 200222165 A UPAB: 20020621
NOVELTY - **Non-genetic** based protein disease markers for obesity, osteoporosis, **diabetes**, osteoathritis and hypertension, are new.
DETAILED DESCRIPTION - **Non-genetic** based protein disease markers for obesity, osteoporosis, **diabetes**, osteoathritis and hypertension, are new, where markers for obesity (n=34), osteoporosis (n=20), **diabetes** (n=9), osteoathritis (n=1) and

hypertension (n=9) are listed in the specification.

INDEPENDENT CLAIMS are also included for the following:

(1) determining a disease state of a subject suspected of having obesity, osteoporosis, **diabetes**, osteoathritis or hypertension comprising:

(a) obtaining a sample containing protein;

(b) measuring levels of protein markers of the disease state, where the markers are given in the specification; and

(c) comparing with levels in controls from disease-free subjects/control standards;

(2) binding reagents specific for the proteins, optionally bound to a detectable label;

(3) a standardized two-dimensional electrophoretic protein distribution from a sample (optionally human serum) from a subject having obesity, osteoporosis, **diabetes**, osteoathritis or hypertension (and optionally being treated with pharmaceuticals);

(4) protein markers comprising a composition of two or more proteins which individually do not have significantly different levels between disease/control samples in a method as in (1), but produce a combined value which is significantly different, and methods and binding reagents as in (1) and (2) relating to the markers;

(5) protein submarkers not altered statistically significantly in the method as in (1) but altered in tandem/opposite in level and direction to protein markers, and methods and binding reagents as in (1) and (2) relating to the markers;

(6) generating an index marker for a particular physiological state comprising:

(a) determining protein markers that differ between samples from a subject with a disease state and a control sample;

(b) selecting two or more of the markers;

(c) combining the values for the markers and determining where the combination of values is altered in a manner of greater statistical significance;

(7) index markers comprising two or more protein markers determined by (6);

(8) cloning a gene encoding a **protein marker** comprising:

(a) determining a partial amino acid sequence of the protein;

(b) deducing a nucleotide sequence for a gene encoding the protein; and

(c) isolating or synthesizing a gene encoding the nucleotide sequence; and

(9) polynucleotides encoding the proteins, and antisense sequences inhibiting gene expression.

ACTIVITY - Anorectic; osteopathic; antidiabetic; antiarthritic; hypotensive. No biological data is given.

MECHANISM OF ACTION - None given.

USE - The markers and a new method are useful to diagnose obesity, osteoporosis, **diabetes**, osteoathritis or hypertension in individuals. Marker levels may also be used to determine disease severity. The markers and method can also be used to monitor the efficacy of therapy for the conditions, by comparing marker levels between samples from a subject taken at different times. The markers identified may also be drug development targets for the diseases. The protein markers can be used to screen compounds for biological activity against the diseases, which may be included with a carrier in pharmaceutical compositions useful to treat the disease states. The markers are useful to screen candidate compounds for detection of or therapeutic activity against disease states, and to identify biological pathways involved in disease states. They are also useful to identify synergistic agents which may be included in pharmaceutical compositions (all claimed).

Dwg.0/10

ACCESSION NUMBER: 2002-362307 [39] WPIDS
DOC. NO. CPI: C2002-102544

TITLE: New **non-genetic** based protein disease markers for obesity, osteoporosis, **diabetes**, osteoathritis and hypertension, useful in diagnosis and monitoring of treatment for these diseases and to screen for therapeutic compounds.

DERWENT CLASS: B04 D16

INVENTOR(S): ANDERSON, N L; MYERS, T G; PIEPER, R; STEINER, S; TAYLOR, J; MYERS, T; REMBERT, P

PATENT ASSIGNEE(S): (ANDE-I) ANDERSON N L; (MYER-I) MYERS T G; (PIEP-I) PIEPER R; (STEI-I) STEINER S; (TAYL-I) TAYLOR J; (LARG-N) LARGE SCALE PROTEOMICS CORP

COUNTRY COUNT: 97

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2002022165	A1	20020321	(200239)*	EN	63
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW					
US 2002072492	A1	20020613	(200243)		
AU 2001088973	A	20020326	(200251)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2002022165	A1	WO 2001-US28268	20010912
US 2002072492	A1 CIP of	US 2000-660242	20000912
		US 2001-886271	20010622
AU 2001088973	A	AU 2001-88973	20010912

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2001088973	A Based on	WO 2002022165

PRIORITY APPLN. INFO: US 2001-886271 20010622; US 2000-660242 20000912

L15 ANSWER 2 OF 9 USPATFULL on STN

TI Novel 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 molecules and uses therefor

AB The invention provides isolated nucleic acids molecules, designated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 gene has been introduced or disrupted. The invention still further provides isolated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 proteins, fusion proteins, antigenic peptides and anti-25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:12981 USPATFULL
TITLE: Novel 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 molecules and uses therefor
INVENTOR(S): Curtis, Rory A. J., Ashland, MA, UNITED STATES
Logan, Thomas Joseph, Springfield, PA, UNITED STATES
Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
Meyers, Rachel E., Newton, MA, UNITED STATES
Williamson, Mark J., Saugus, MA, UNITED STATES
Rudolph-Owen, Laura A., Medford, MA, UNITED STATES
Chun, Miyoung, Belmont, MA, UNITED STATES
Tsai, Fong-Ying, Newton, MA, UNITED STATES
PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004009501	A1	20040115	
APPLICATION INFO.:	US 2003-377072	A1	20030227	(10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-895860, filed on 29 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2000-723806, filed on 28 Nov 2000, PENDING Continuation-in-part of Ser. No. US 2001-843297, filed on 25 Apr 2001, GRANTED, Pat. No. US 6569667 Continuation-in-part of Ser. No. US 2001-861801, filed on 21 May 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-816494, filed on 23 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2001-888911, filed on 25 Jun 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-908664, filed on 17 Jul 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-935291, filed on 21 Aug 2001, ABANDONED

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-215370P	20000629	(60)
	US 2000-187455P	20000307	(60)
	US 2000-199801P	20000426	(60)
	US 2000-205508P	20000519	(60)
	US 2000-213688P	20000623	(60)
	US 2000-218675P	20000717	(60)
	US 2000-250932P	20001130	(60)
	US 2000-226504P	20000821	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Jean M. Silveri, 75 Sidney Street, Cambridge, MA, 02139
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
LINE COUNT: 16123
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 3 OF 9 USPATFULL on STN
TI Novel 27875, 22025 ,27420, 17906, 16319, 55092 and 10218 molecules and uses therefor
AB The invention provides isolated nucleic acids molecules, designated 27875, 22025, 27420, 16319, 55092 and 10218 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27875, 22025, 27420, 16319, 55092 and 10218 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 27875, 22025, 27420, 16319, 55092 and 10218 gene has been introduced or disrupted. The invention still further provides isolated 27875, 22025, 27420, 17906, 16319, 55092 or 10218 proteins, fusion proteins, antigenic peptides and anti-27875, 22025, 27420, 17906, 16319, 55092 or 10218

antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:7776 USPATFULL
TITLE: Novel 27875, 22025 ,27420, 17906, 16319, 55092 and 10218 molecules and uses therefor
INVENTOR(S): Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
White, David, Braintree, MA, UNITED STATES
Robison, Keith E., Wilmington, MA, UNITED STATES
MacBeth, Kyle J., Boston, MA, UNITED STATES
Carroll, Joseph M., Cambridge, MA, UNITED STATES
Cook, William James, Hanover, NH, UNITED STATES
Meyers, Rachel E., Newton, MA, UNITED STATES
Chun, Miyoung, Belmont, MA, UNITED STATES
Williamson, Mark J., Saugus, MA, UNITED STATES
PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004006016	A1	20040108
APPLICATION INFO.:	US 2003-386414	A1	20030311 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-426282, filed on 25 Oct 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-668266, filed on 22 Sep 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-330970, filed on 11 Jun 1999, GRANTED, Pat. No. US 6146876 Continuation-in-part of Ser. No. US 2000-724599, filed on 28 Nov 2000, PENDING Continuation-in-part of Ser. No. US 2001-860193, filed on 16 May 2001, PENDING Continuation-in-part of Ser. No. US 2000-571689, filed on 16 May 2000, ABANDONED Continuation-in-part of Ser. No. US 2002-283023, filed on 29 Oct 2002, PENDING Continuation-in-part of Ser. No. US 2001-10943, filed on 6 Dec 2001, PENDING Continuation-in-part of Ser. No. US 2001-833082, filed on 10 Apr 2001, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-335044P	20011031 (60)
	US 2000-254037P	20001207 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
LINE COUNT: 25349
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 4 OF 9 USPATFULL on STN
TI Novel 38594, 57312, 53659, 57250, 63760, 49938, 32146, 57259, 67118, 67067, 62092, 8099, 46455, 54414, 53763, 67076, 67102, 44181, 67084FL, 67084ALT, FBH58295FL, 57255, and 57255alt molecules and uses therefor
AB The invention provides isolated nucleic acids molecules, designated 38594, 57312, 53659, 57250, 63760, 49938, 32146, 57259, 67118, 67067, 62092, 8099, 46455, 54414, 53763, 67076, 67102, 44181, 67084FL, 67084ALT, FBH58295FL, 57255, and 57255alt nucleic acid molecules, which encode transporter molecules, including sugar transporters, organic anion transporters, amino acid transporters, and phospholipid transporters. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 38594, 57312, 53659, 57250, 63760, 49938, 32146, 57259, 67118, 67067, 62092, 8099,

46455, 54414, 53763, 67076, 67102, 44181, 67084FL, 67084ALT, FBH58295FL, 57255, and 57255alt nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a 38594, 57312, 53659, 57250, 63760, 49938, 32146, 57259, 67118, 67067, 62092, 8099, 46455, 54414, 53763, 67076, 67102, 44181, 67084FL, 67084ALT, FBH58295FL, 57255, and 57255alt gene has been introduced or disrupted. The invention still further provides isolated 38594, 57312, 53659, 57250, 63760, 49938, 32146, 57259, 67118, 67067, 62092, 8099, 46455, 54414, 53763, 67076, 67102, 44181, 67084FL, 67084ALT, FBH58295FL, 57255, and 57255alt polypeptides, fusion polypeptides, antigenic peptides and anti-38594, 57312, 53659, 57250, 63760, 49938, 32146, 57259, 67118, 67067, 62092, 8099, 46455, 54414, 53763, 67076, 67102, 44181, 67084FL, 67084ALT, FBH58295FL, 57255, and 57255alt antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:207317 USPATFULL

TITLE: Novel 38594, 57312, 53659, 57250, 63760, 49938, 32146, 57259, 67118, 67067, 62092, 8099, 46455, 54414, 53763, 67076, 67102, 44181, 67084FL, 67084ALT, FBH58295FL, 57255, and 57255alt molecules and uses therefor

INVENTOR(S): Curtis, Rory A.J., Framingham, MA, UNITED STATES
Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
Meyers, Rachel E., Newton, MA, UNITED STATES

PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., Cambridge, MA (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003143675	A1	20030731	
APPLICATION INFO.:	US 2002-154419	A1	20020522	(10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-858194, filed on 14 May 2001, PENDING Continuation-in-part of Ser. No. US 2001-895811, filed on 29 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2001-919781, filed on 31 Jul 2001, PENDING Continuation-in-part of Ser. No. US 2001-957664, filed on 19 Sep 2001, PENDING Continuation-in-part of Ser. No. US 2001-964295, filed on 25 Sep 2001, PENDING Continuation-in-part of Ser. No. US 2001-972724, filed on 5 Oct 2001, PENDING Continuation-in-part of Ser. No. US 2001-2769, filed on 14 Nov 2001, PENDING Continuation-in-part of Ser. No. US 2001-24623, filed on 17 Dec 2001, PENDING Continuation-in-part of Ser. No. US 2002-55025, filed on 22 Jan 2002, PENDING

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-204211P	20000512	(60)
	US 2000-215376P	20000629	(60)
	US 2000-221769P	20000731	(60)
	US 2000-233790P	20000919	(60)
	US 2000-235107P	20000925	(60)
	US 2000-238336P	20001005	(60)
	US 2000-248364P	20001114	(60)
	US 2000-248878P	20001115	(60)
	US 2000-256240P	20001215	(60)
	US 2000-256588P	20001218	(60)
	US 2000-258028P	20001221	(60)
	US 2001-263169P	20010122	(60)
	US 2001-263169P	20010122	(60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Intellectual Property Group, MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street, Cambridge, MA, 02139
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 252 Drawing Page(s)
LINE COUNT: 45817
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 5 OF 9 USPATFULL on STN
TI 68723, sodium/glucose cotransporter family members and uses therefor
AB The invention provides isolated nucleic acids molecules, designated 68723 nucleic acid molecules, which encode novel sodium/glucose cotransporter family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 68723 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 68723 gene has been introduced or disrupted. The invention still further provides isolated 68723 proteins, fusion proteins, antigenic peptides and anti-68723 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:78533 USPATFULL
TITLE: 68723, sodium/glucose cotransporter family members and uses therefor
INVENTOR(S): Curtis, Rory A.J., Framingham, MA, UNITED STATES
Chen, Hong, Newton, MA, UNITED STATES
PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003054453	A1	20030320	
APPLICATION INFO.:	US 2002-119988	A1	20020410	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2001-282764P	20010410	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Jean M. Silveri, MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street, Cambridge, MA, 02139
NUMBER OF CLAIMS: 43
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 6315
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 6 OF 9 USPATFULL on STN
TI 18607, a novel human calcium channel
AB The invention provides isolated nucleic acids molecules, designated TLCC nucleic acid molecules, which encode novel TRP-like calcium channel molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing TLCC nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a TLCC gene has been introduced or disrupted. The invention still further provides isolated TLCC proteins, fusion proteins, antigenic peptides and anti-TLCC antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:258807 USPATFULL
TITLE: 18607, a novel human calcium channel

INVENTOR(S): Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
Curtis, Rory A.J., Southborough, MA, UNITED STATES
Lora, Jose M., Arlington, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002142377	A1	20021003
APPLICATION INFO.:	US 2001-789481	A1	20010220 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-634669, filed on 8 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-583373, filed on 31 May 2000, PENDING Continuation-in-part of Ser. No. US 2000-510706, filed on 22 Feb 2000, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109
NUMBER OF CLAIMS: 44
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 26 Drawing Page(s)
LINE COUNT: 5230
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 7 OF 9 USPATFULL on STN
TI 25869, a novel human carboxylesterase and uses thereof
AB The invention provides isolated nucleic acid molecules, designated COE-1 nucleic acid molecules, which encode novel carboxylesterase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing COE-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a COE-1 gene has been introduced or disrupted. The invention still further provides isolated COE-1 proteins, fusion proteins, antigenic peptides and anti-COE-1 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:148643 USPATFULL
TITLE: 25869, a novel human carboxylesterase and uses thereof
INVENTOR(S): Curtis, Rory A.J., Southborough, MA, UNITED STATES
Logan, Thomas Joseph, Needham, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002076786	A1	20020620
APPLICATION INFO.:	US 2001-895860	A1	20010629 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-215370P	20000629 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109
NUMBER OF CLAIMS: 32
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Page(s)
LINE COUNT: 5139
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 8 OF 9 USPATFULL on STN
TI **Non-genetic** based protein disease markers
AB Protein disease markers for obesity, osteoporosis, **diabetes**, osteoarthritis and hypertension are disclosed. These markers are not inherited or of genetic origin as they were not found in identical twins

of the affected individual. Methods and uses for diagnostic, therapeutic and drug discovery are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:141506 USPATFULL
TITLE: **Non-genetic** based protein disease markers
INVENTOR(S): Myers, Timothy G., Kensington, MD, UNITED STATES
Pieper, Rembert, Washington, DC, UNITED STATES
Taylor, John, JR., Clayton, NC, UNITED STATES
Steiner, Sandra, Gaithersburg, MD, UNITED STATES
Anderson, N. Leigh, Washington, DC, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002072492	A1	20020613	
APPLICATION INFO.:	US 2001-886271	A1	20010622	(9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-660242, filed on 12 Sep 2000, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Dean H. Nakamura, Roylance Abrams Berdo & Goodman, 1300 19th Street, N.W., Washington, DC, 20036
NUMBER OF CLAIMS: 55
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 1425
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 9 OF 9 USPATFULL on STN
TI Methods and compositions for elucidating relative protein expression levels in cells
AB The present invention relates generally to methods and compositions for the identification of differential protein expression patterns and concomitantly the active genetic regions that are directly or indirectly involved in different tissue types, disease states, or other cellular differences desirable for diagnosis or for targets for drug therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:188396 USPATFULL
TITLE: Methods and compositions for elucidating relative protein expression levels in cells
INVENTOR(S): Link, Charles J., Des Moines, IA, United States
Seregina, Tatiana, Ames, IA, United States
Vahanian, Nicholas N., Ames, IA, United States
Higginbotham, James N., Ames, IA, United States
Ramsey, W. Jay, Ames, IA, United States
Powers, Bradley J., Ames, IA, United States
Shulka, Sachet A., Ames, IA, United States
Young, Won Bin, Ames, IA, United States

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2001034028	A1	20011025	
APPLICATION INFO.:	US 2001-811842	A1	20010319	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-190678P	20000320	(60)
	US 2000-198722P	20000420	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ZARLEY MCKEE THOMTE VOORHEES & SEASE PLC, SUITE 3200, 801 GRAND AVENUE, DES MOINES, IA, 50309-2721

NUMBER OF CLAIMS: 52
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Page(s)
LINE COUNT: 2290
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 13:10:45 ON 12 MAR 2004)

FILE 'MEDLINE, BIOSIS, BIOBUSINESS, WPIDS, FSTA, JICST-EPLUS, EMBASE, DGENE, USPATFULL' ENTERED AT 13:11:13 ON 12 MAR 2004

L1 2389 S PROTEIN MARKER
L2 368909 S OBESITY
L3 845017 S HYPERTENSION
L4 1028410 S DIABETES
L5 270109 S OSTEOARTHRITIS
L6 232226 S OSTEOPOROSIS
L7 218 S L1 AND L2
L8 0 S L1 () L3
L9 267 S L1 AND L3
L10 308 S L1 AND L4
L11 226 S L1 AND L5
L12 209 S L1 AND L6
L13 8 S L7 AND NON-GENETIC
L14 9 S L9 AND NON-GENETIC
L15 9 S L10 AND NON-GENETIC

=> s l11 and NON-GENETIC
L16 2 L11 AND NON-GENETIC

=> d l16 ti abs ibib tot

L16 ANSWER 1 OF 2 USPATFULL on STN
TI Novel 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 molecules and uses therefor
AB The invention provides isolated nucleic acids molecules, designated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 gene has been introduced or disrupted. The invention still further provides isolated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 proteins, fusion proteins, antigenic peptides and anti-25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:12981 USPATFULL
TITLE: Novel 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 molecules and uses therefor
INVENTOR(S): Curtis, Rory A. J., Ashland, MA, UNITED STATES
Logan, Thomas Joseph, Springfield, PA, UNITED STATES
Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
Meyers, Rachel E., Newton, MA, UNITED STATES
Williamson, Mark J., Saugus, MA, UNITED STATES

	Rudolph-Owen, Laura A., Medford, MA, UNITED STATES Chun, Miyoung, Belmont, MA, UNITED STATES Tsai, Fong-Ying, Newton, MA, UNITED STATES
PATENT ASSIGNEE(S):	Millennium Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009501	A1	20040115
APPLICATION INFO.:	US 2003-377072	A1	20030227 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-895860, filed on 29 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2000-723806, filed on 28 Nov 2000, PENDING Continuation-in-part of Ser. No. US 2001-843297, filed on 25 Apr 2001, GRANTED, Pat. No. US 6569667 Continuation-in-part of Ser. No. US 2001-861801, filed on 21 May 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-816494, filed on 23 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2001-888911, filed on 25 Jun 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-908664, filed on 17 Jul 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-935291, filed on 21 Aug 2001, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-215370P	20000629 (60)
	US 2000-187455P	20000307 (60)
	US 2000-199801P	20000426 (60)
	US 2000-205508P	20000519 (60)
	US 2000-213688P	20000623 (60)
	US 2000-218675P	20000717 (60)
	US 2000-250932P	20001130 (60)
	US 2000-226504P	20000821 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Jean M. Silveri, 75 Sidney Street, Cambridge, MA, 02139
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
LINE COUNT: 16123
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 2 OF 2 USPATFULL on STN
TI **Non-genetic** based protein disease markers
AB Protein disease markers for obesity, osteoporosis, diabetes, **osteoarthritis** and hypertension are disclosed. These markers are not inherited or of genetic origin as they were not found in identical twins of the affected individual. Methods and uses for diagnostic, therapeutic and drug discovery are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:141506 USPATFULL
TITLE: **Non-genetic** based protein disease markers
INVENTOR(S): Myers, Timothy G., Kensington, MD, UNITED STATES
Pieper, Rembert, Washington, DC, UNITED STATES
Taylor, John, JR., Clayton, NC, UNITED STATES
Steiner, Sandra, Gaithersburg, MD, UNITED STATES
Anderson, N. Leigh, Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002072492	A1	20020613
APPLICATION INFO.:	US 2001-886271	A1	20010622 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-660242, filed

                    on 12 Sep 2000, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Dean H. Nakamura, Roylance Abrams Berdo & Goodman, 1300
                    19th Street, N.W., Washington, DC, 20036
NUMBER OF CLAIMS: 55
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 1425
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

     (FILE 'HOME' ENTERED AT 13:10:45 ON 12 MAR 2004)

     FILE 'MEDLINE, BIOSIS, BIOBUSINESS, WPIDS, FSTA, JICST-EPLUS, EMBASE,
     DGENE, USPATFULL' ENTERED AT 13:11:13 ON 12 MAR 2004
L1   2389 S PROTEIN MARKER
L2   368909 S OBESITY
L3   845017 S HYPERTENSION
L4   1028410 S DIABETES
L5   270109 S OSTEOARTHRITIS
L6   232226 S OSTEOPOROSIS
L7   218 S L1 AND L2
L8   0 S L1 () L3
L9   267 S L1 AND L3
L10   308 S L1 AND L4
L11   226 S L1 AND L5
L12   209 S L1 AND L6
L13   8 S L7 AND NON-GENETIC
L14   9 S L9 AND NON-GENETIC
L15   9 S L10 AND NON-GENETIC
L16   2 S L11 AND NON-GENETIC

=> s l12 and NON-GENETIC
L17   4 L12 AND NON-GENETIC

=> d l17 ti abs ibib tot

L17 ANSWER 1 OF 4 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
TI   New **non-genetic** based protein disease markers for
     obesity, **osteoporosis**, diabetes, osteoathritis and hypertension,
     useful in diagnosis and monitoring of treatment for these diseases and to
     screen for therapeutic compounds.
AN   2002-362307 [39]   WPIDS
AB   WO 200222165 A UPAB: 20020621
     NOVELTY - **Non-genetic** based protein disease markers
     for obesity, **osteoporosis**, diabetes, osteoathritis and
     hypertension, are new.
          DETAILED DESCRIPTION - **Non-genetic** based protein
     disease markers for obesity, **osteoporosis**, diabetes,
     osteoathritis and hypertension, are new, where markers for obesity (n=34),
     osteoporosis (n=20), diabetes (n=9), osteoathritis (n=1) and
     hypertension (n=9) are listed in the specification.
          INDEPENDENT CLAIMS are also included for the following:
          (1) determining a disease state of a subject suspected of having
     obesity, **osteoporosis**, diabetes, osteoathritis or hypertension
     comprising:
          (a) obtaining a sample containing protein;
          (b) measuring levels of protein markers of the disease state, where
     the markers are given in the specification; and
          (c) comparing with levels in controls from disease-free
     subjects/control standards;

(2) binding reagents specific for the proteins, optionally bound to a detectable label;

(3) a standardized two-dimensional electrophoretic protein distribution from a sample (optionally human serum) from a subject having obesity, **osteoporosis**, diabetes, osteoathritis or hypertension (and optionally being treated with pharmaceuticals);

(4) protein markers comprising a composition of two or more proteins which individually do not have significantly different levels between disease/control samples in a method as in (1), but produce a combined value which is significantly different, and methods and binding reagents as in (1) and (2) relating to the markers;

(5) protein submarkers not altered statistically significantly in the method as in (1) but altered in tandem/opposite in level and direction to protein markers, and methods and binding reagents as in (1) and (2) relating to the markers;

(6) generating an index marker for a particular physiological state comprising:

(a) determining protein markers that differ between samples from a subject with a disease state and a control sample;

(b) selecting two or more of the markers;

(c) combining the values for the markers and determining where the combination of values is altered in a manner of greater statistical significance;

(7) index markers comprising two or more protein markers determined by (6);

(8) cloning a gene encoding a **protein marker** comprising:

(a) determining a partial amino acid sequence of the protein;

(b) deducing a nucleotide sequence for a gene encoding the protein; and

(c) isolating or synthesizing a gene encoding the nucleotide sequence; and

(9) polynucleotides encoding the proteins, and antisense sequences inhibiting gene expression.

ACTIVITY - Anorectic; osteopathic; antidiabetic; antiarthritic; hypotensive. No biological data is given.

MECHANISM OF ACTION - None given.

USE - The markers and a new method are useful to diagnose obesity, **osteoporosis**, diabetes, osteoathritis or hypertension in individuals. Marker levels may also be used to determine disease severity. The markers and method can also be used to monitor the efficacy of therapy for the conditions, by comparing marker levels between samples from a subject taken at different times. The markers identified may also be drug development targets for the diseases. The protein markers can be used to screen compounds for biological activity against the diseases, which may be included with a carrier in pharmaceutical compositions useful to treat the disease states. The markers are useful to screen candidate compounds for detection of or therapeutic activity against disease states, and to identify biological pathways involved in disease states. They are also useful to identify synergistic agents which may be included in pharmaceutical compositions (all claimed).

Dwg.0/10

ACCESSION NUMBER: 2002-362307 [39] WPIDS
DOC. NO. CPI: C2002-102544
TITLE: New **non-genetic** based protein disease markers for obesity, **osteoporosis**, diabetes, osteoathritis and hypertension, useful in diagnosis and monitoring of treatment for these diseases and to screen for therapeutic compounds.
DERWENT CLASS: B04 D16
INVENTOR(S): ANDERSON, N L; MYERS, T G; PIEPER, R; STEINER, S; TAYLOR, J; MYERS, T; REMBERT, P
PATENT ASSIGNEE(S): (ANDE-I) ANDERSON N L; (MYER-I) MYERS T G; (PIEP-I) PIEPER R; (STEI-I) STEINER S; (TAYL-I) TAYLOR J; (LARG-N)

LARGE SCALE PROTEOMICS CORP
COUNTRY COUNT: 97
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2002022165	A1	20020321	(200239)*	EN	63
US 2002072492	A1	20020613	(200243)		
AU 2001088973	A	20020326	(200251)		

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2002022165	A1	WO 2001-US28268	20010912
US 2002072492	A1 CIP of	US 2000-660242	20000912
		US 2001-886271	20010622
AU 2001088973	A	AU 2001-88973	20010912

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 2001088973	A	Based on	WO 2002022165

PRIORITY APPLN. INFO: US 2001-886271 20010622; US 2000-660242 20000912

L17 ANSWER 2 OF 4 USPATFULL on STN

TI Novel 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 molecules and uses therefor

AB The invention provides isolated nucleic acids molecules, designated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 gene has been introduced or disrupted. The invention still further provides isolated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 proteins, fusion proteins, antigenic peptides and anti-25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:12981 USPATFULL
TITLE: Novel 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 molecules and uses therefor
INVENTOR(S): Curtis, Rory A. J., Ashland, MA, UNITED STATES
Logan, Thomas Joseph, Springfield, PA, UNITED STATES
Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
Meyers, Rachel E., Newton, MA, UNITED STATES
Williamson, Mark J., Saugus, MA, UNITED STATES

Rudolph-Owen, Laura A., Medford, MA, UNITED STATES
Chun, Miyoung, Belmont, MA, UNITED STATES
Tsai, Fong-Ying, Newton, MA, UNITED STATES
PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009501	A1	20040115
APPLICATION INFO.:	US 2003-377072	A1	20030227 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-895860, filed on 29 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2000-723806, filed on 28 Nov 2000, PENDING Continuation-in-part of Ser. No. US 2001-843297, filed on 25 Apr 2001, GRANTED, Pat. No. US 6569667 Continuation-in-part of Ser. No. US 2001-861801, filed on 21 May 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-816494, filed on 23 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2001-888911, filed on 25 Jun 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-908664, filed on 17 Jul 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-935291, filed on 21 Aug 2001, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-215370P	20000629 (60)
	US 2000-187455P	20000307 (60)
	US 2000-199801P	20000426 (60)
	US 2000-205508P	20000519 (60)
	US 2000-213688P	20000623 (60)
	US 2000-218675P	20000717 (60)
	US 2000-250932P	20001130 (60)
	US 2000-226504P	20000821 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Jean M. Silveri, 75 Sidney Street, Cambridge, MA, 02139
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
LINE COUNT: 16123
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 3 OF 4 USPATFULL on STN
TI Novel 27875, 22025 ,27420, 17906, 16319, 55092 and 10218 molecules and uses therefor
AB The invention provides isolated nucleic acids molecules, designated 27875, 22025, 27420, 16319, 55092 and 10218 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27875, 22025, 27420, 16319, 55092 and 10218 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 27875, 22025, 27420, 16319, 55092 and 10218 gene has been introduced or disrupted. The invention still further provides isolated 27875, 22025, 27420, 17906, 16319, 55092 or 10218 proteins, fusion proteins, antigenic peptides and anti-27875, 22025, 27420, 17906, 16319, 55092 or 10218 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:7776 USPATFULL
TITLE: Novel 27875, 22025 ,27420, 17906, 16319, 55092 and 10218 molecules and uses therefor
INVENTOR(S): Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
White, David, Braintree, MA, UNITED STATES

Robison, Keith E., Wilmington, MA, UNITED STATES
MacBeth, Kyle J., Boston, MA, UNITED STATES
Carroll, Joseph M., Cambridge, MA, UNITED STATES
Cook, William James, Hanover, NH, UNITED STATES
Meyers, Rachel E., Newton, MA, UNITED STATES
Chun, Miyoung, Belmont, MA, UNITED STATES
Williamson, Mark J., Saugus, MA, UNITED STATES
PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004006016	A1	20040108
APPLICATION INFO.:	US 2003-386414	A1	20030311 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-426282, filed on 25 Oct 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-668266, filed on 22 Sep 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-330970, filed on 11 Jun 1999, GRANTED, Pat. No. US 6146876 Continuation-in-part of Ser. No. US 2000-724599, filed on 28 Nov 2000, PENDING Continuation-in-part of Ser. No. US 2001-860193, filed on 16 May 2001, PENDING Continuation-in-part of Ser. No. US 2000-571689, filed on 16 May 2000, ABANDONED Continuation-in-part of Ser. No. US 2002-283023, filed on 29 Oct 2002, PENDING Continuation-in-part of Ser. No. US 2001-10943, filed on 6 Dec 2001, PENDING Continuation-in-part of Ser. No. US 2001-833082, filed on 10 Apr 2001, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-335044P	20011031 (60)
	US 2000-254037P	20001207 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
LINE COUNT: 25349
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 4 OF 4 USPATFULL on STN
TI **Non-genetic** based protein disease markers
AB Protein disease markers for obesity, **osteoporosis**, diabetes, osteoarthritis and hypertension are disclosed. These markers are not inherited or of genetic origin as they were not found in identical twins of the affected individual. Methods and uses for diagnostic, therapeutic and drug discovery are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:141506 USPATFULL
TITLE: **Non-genetic** based protein disease markers
INVENTOR(S): Myers, Timothy G., Kensington, MD, UNITED STATES
Pieper, Rembert, Washington, DC, UNITED STATES
Taylor, John, JR., Clayton, NC, UNITED STATES
Steiner, Sandra, Gaithersburg, MD, UNITED STATES
Anderson, N. Leigh, Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002072492	A1	20020613
APPLICATION INFO.:	US 2001-886271	A1	20010622 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-660242, filed

	on 12 Sep 2000, PENDING
DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	Dean H. Nakamura, Roylance Abrams Berdo & Goodman, 1300 19th Street, N.W., Washington, DC, 20036
NUMBER OF CLAIMS:	55
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	10 Drawing Page(s)
LINE COUNT:	1425

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
!!AA_SEQUENCE 1.0
ID   APOH_HUMAN     STANDARD;      PRT;   345 AA.
AC   P02749;
DT   21-JUL-1986 (Rel. 01, Created)
DT   01-JUN-1994 (Rel. 29, Last sequence update)
DT   10-OCT-2003 (Rel. 42, Last annotation update)
DE   Beta-2-glycoprotein I precursor (Apolipoprotein H) (Apo-H) (B2GPI)
DE   (Beta(2)GPI) (Activated protein C-binding protein) (APC inhibitor).
GN   APOH OR B2G1.
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   SEQUENCE FROM N.A.
RC   TISSUE=Liver;
RX   MEDLINE=91315408; PubMed=1650181;
RA   Steinkasserer A., Estaller C., Weiss E., Sim R.B., Day A.J.;
RT   "Complete nucleotide and deduced amino acid sequence of human beta 2-
RT   glycoprotein I.";
RL   Biochem. J. 277:387-391(1991).
RN   [2]
RP   SEQUENCE FROM N.A.
RC   TISSUE=Liver;
RX   MEDLINE=92008618; PubMed=1655523;
RA   Kristensen T., Schousboe I., Boel E., Mulvihill E.M., Hansen R.R.,
RA   Moeller K.B., Moeller N.P.H., Sottrup-Jensen L.;
RT   "Molecular cloning and mammalian expression of human beta
RT   2-glycoprotein I cDNA.";
RL   FEBS Lett. 289:183-186(1991).
RN   [3]
RP   SEQUENCE FROM N.A.
RC   TISSUE=Liver;
RX   MEDLINE=92084151; PubMed=1748314;
RA   Mehdi H., Nunn M., Steel D.M., Whitehead A.S., Perez M., Walker L.,
RA   Peeples M.E.;
RT   "Nucleotide sequence and expression of the human gene encoding
RT   apolipoprotein H (beta 2-glycoprotein I).";
RL   Gene 108:293-298(1991).
RN   [4]
RP   SEQUENCE FROM N.A.
RX   MEDLINE=92273779; PubMed=1339416;
RA   Day J.R., O'Hara P.J., Grant F.J., Lofton-Day C.E., Berkaw M.N.,
RA   Werner P., Arnaud P.;
RT   "Molecular cloning and sequence analysis of the cDNA encoding human
RT   apolipoprotein H (beta 2-glycoprotein I).";
RL   Int. J. Clin. Lab. Res. 21:256-263(1992).
RN   [5]
RP   SEQUENCE FROM N.A.
RX   MEDLINE=92135065; PubMed=1777418;
RA   Matsuura E., Igarashi M., Igarashi Y., Nagae H., Ichikawa K.,
RA   Yasuda T., Koike T.;
RT   "Molecular definition of human beta 2-glycoprotein I (beta 2-GPI) by
RT   cDNA cloning and inter-species differences of beta 2-GPI in
RT   alternation of anticardiolipin binding.";
RL   Int. Immunol. 3:1217-1221(1991).
RN   [6]
RP   SEQUENCE FROM N.A.
RX   MEDLINE=99115472; PubMed=9914524;
RA   Okkels H., Rasmussen T.E., Sanghera D.K., Kamboh M.I., Kristensen T.;
RT   "Structure of the human beta2-glycoprotein I (apolipoprotein H)
RT   gene.";
RL   Eur. J. Biochem. 259:435-440(1999).
RN   [7]
RP   SEQUENCE FROM N.A.
RC   TISSUE=Liver;
RX   MEDLINE=22388257; PubMed=12477932;
RA   Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA   Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA   Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA   Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA   Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA   Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA   Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA   Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA   Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA   Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA   Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA   Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA   Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA   Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA   Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA   Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA   Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT   "Generation and initial analysis of more than 15,000 full-length
RT   human and mouse cDNA sequences.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN   [8]
RP   SEQUENCE OF 20-345, CARBOHYDRATE-LINKAGE SITES, AND DISULFIDE BONDS.
RX   MEDLINE=84222015; PubMed=6587378;
RA   Lozier J., Takahashi N., Putnam F.W.;
RT   "Complete amino acid sequence of human plasma beta 2-glycoprotein I.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:3640-3644(1984).
RN   [9]
RP   SEQUENCE OF 20-38.
RC   TISSUE=Follicular fluid;
RX   MEDLINE=21148139; PubMed=11250549;
RA   Aleporou-Marinou V., Pappa H., Yalouris P., Patargias T.;
RT   "Purification of apolipoprotein H (beta 2-glycoprotein I)-like protein
RT   from human follicular fluid.";
RL   Comp. Biochem. Physiol. 128B:537-542(2001).
RN   [10]
RP   DISULFIDE BONDS IN C-TERMINAL DOMAIN.
RX   MEDLINE=93050249; PubMed=1426288;
RA   Steinkasserer A., Barlow P.N., Willis A.C., Kertesz Z.,
RA   Campbell I.D., Sim R.B., Norman D.G.;
RT   "Activity, disulphide mapping and structural modelling of the fifth
RT   domain of human beta 2-glycoprotein I.";
RL   FEBS Lett. 313:193-197(1992).
RN   [11]
RP   STRUCTURE OF CARBOHYDRATES.
RX   MEDLINE=97299942; PubMed=9155091;
RA   Gambino R., Ruiu G., Pagano G., Cassader M.;
RT   "Qualitative analysis of the carbohydrate composition of
RT   apolipoprotein H.";
RL   J. Protein Chem. 16:205-212(1997).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS).
RC   TISSUE=Plasma;
RX   MEDLINE=99437994; PubMed=10508150;
RA   Bouma B., de Groot P.G., van Den Elsen J.M.H., Ravelli R.B.G.,
RA   Schouten A., Simmelink M.J.A., Derksen R.H.W.M., Kroon J., Gros P.;
RT   "Adhesion mechanism of human beta(2)-glycoprotein I to phospholipids
RT   based on its crystal structure.";
RL   EMBO J. 18:5166-5174(1999).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (2.87 ANGSTROMS).
RX   MEDLINE=20031634; PubMed=10562535;
RA   Schwarzenbacher R., Zeth K., Diederichs K., Gries A., Kostner G.M.,
RA   Laggner P., Prassl R.;
RT   "Crystal structure of human beta2-glycoprotein I: implications for
RT   phospholipid binding and the antiphospholipid syndrome.";
RL   EMBO J. 18:6228-6239(1999).
RN   [14]
RP   VARIANT LEU-266.
RX   MEDLINE=93273313; PubMed=8099061;
RA   Steinkasserer A., Doerner C., Wuerzner R., Sim R.B.;
RT   "Human beta 2-glycoprotein I: molecular analysis of DNA and amino
RT   acid polymorphism.";
RL   Hum. Genet. 91:401-402(1993).
RN   [15]
RP   VARIANT ASN-107.
RX   MEDLINE=97369481; PubMed=9225969;
RA   Sanghera D.K., Kristensen T., Hamman R.F., Kamboh M.I.;
RT   "Molecular basis of the apolipoprotein H (beta 2-glycoprotein I)
RT   protein polymorphism.";
```

```
RL   Hum. Genet. 100:57-62(1997).
RN   [16]
RP   VARIANTS GLY-325 AND SER-335.
RX   MEDLINE=97217791; PubMed=9063752;
RA   Sanghera D.K., Wagenknecht D.R., McIntyre J.A., Kamboh M.I.;
RT   "Identification of structural mutations in the fifth domain of
RT   apolipoprotein H (beta-2-glycoprotein I) which affect phospholipid
RT   binding.";
RL   Hum. Mol. Genet. 6:311-316(1997).
CC   -!- FUNCTION: Binds to various kinds of negatively charged substances
CC       such as heparin, phospholipids, and dextran sulfate. May prevent
CC       activation of the intrinsic blood coagulation cascade by binding
CC       to phospholipids on the surface of damaged cells.
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- TISSUE SPECIFICITY: Expressed by the liver and secreted in plasma.
CC   -!- SIMILARITY: Contains 4 Sushi (SCR) domains.
CC   ---------------------------------------------------------------------
CC   This SWISS-PROT entry is copyright. It is produced through a collaboration
CC   between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC   the European Bioinformatics Institute. There are no restrictions on its
CC   use by non-profit institutions as long as its content is in no way
CC   modified and this statement is not removed. Usage by and for commercial
CC   entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC   or send an email to license@isb-sib.ch).
CC   ---------------------------------------------------------------------
DR   EMBL; X58100; CAA41113.1; -.
DR   EMBL; X53595; CAA37664.1; -.
DR   EMBL; X57847; CAA40977.1; -.
DR   EMBL; M62839; AAA51766.1; -.
DR   EMBL; S80305; AAB21330.1; -.
DR   EMBL; Y11493; CAA72279.1; -.
DR   EMBL; Y11494; CAA72279.1; JOINED.
DR   EMBL; Y11495; CAA72279.1; JOINED.
DR   EMBL; X53595; CAA72279.1; JOINED.
DR   EMBL; Y11496; CAA72279.1; JOINED.
DR   EMBL; Y11497; CAA72279.1; JOINED.
DR   EMBL; Y11498; CAA72279.1; JOINED.
DR   EMBL; Y17754; CAA76845.1; -.
DR   EMBL; BC020703; AAH20703.1; -.
DR   EMBL; BC026283; AAH26283.1; -.
DR   PIR; S17178; NBHU.
DR   PDB; 1QUB; 08-OCT-99.
DR   PDB; 1C1Z; 19-NOV-99.
DR   PDB; 1G4F; 28-MAR-01.
DR   PDB; 1G4G; 28-MAR-01.
DR   Genew; HGNC:616; APOH.
DR   MIM; 138700; -.
DR   InterPro; IPR000436; Sushi_SCR_CCP.
DR   Pfam; PF00084; sushi; 4.
DR   SMART; SM00032; CCP; 4.
KW   Heparin-binding; Glycoprotein; Plasma; Repeat; Sushi; Signal;
KW   Polymorphism; 3D-structure.
FT   SIGNAL        1     19
FT   CHAIN        20    345       BETA-2-GLYCOPROTEIN I.
FT   DOMAIN       22     80       SUSHI 1.
FT   DOMAIN       83    138       SUSHI 2.
FT   DOMAIN      141    201       SUSHI 3.
FT   DOMAIN      204    261       SUSHI 4.
FT   DOMAIN      263    345       SUSHI-LIKE.
FT   DISULFID     23     66
FT   DISULFID     51     79
FT   DISULFID     84    124
FT   DISULFID    110    137
FT   DISULFID    142    188
FT   DISULFID    174    200
FT   DISULFID    205    248
FT   DISULFID    234    260
FT   DISULFID    264    315
FT   DISULFID    300    325
FT   DISULFID    307    345
FT   CARBOHYD    149    149       O-LINKED.
FT   CARBOHYD    162    162       N-LINKED (GLCNAC. . .).
FT   CARBOHYD    183    183       N-LINKED (GLCNAC. . .).
FT   CARBOHYD    193    193       N-LINKED (GLCNAC. . .).
FT   CARBOHYD    253    253       N-LINKED (GLCNAC. . .).
FT   VARIANT     107    107       S -> N (in allele APOH*1; dbSNP:1801692).
FT                                /FTId=VAR_008169.
FT   VARIANT     266    266       V -> L (in 23% of the population;
FT                                dbSNP:4581).
FT                                /FTId=VAR_000673.
FT   VARIANT     325    325       C -> G (loss of phosphatidylserine-
FT                                binding; dbSNP:1801689).
FT                                /FTId=VAR_008170.
FT   VARIANT     335    335       W -> S (in allele APOH*3W; loss of
FT                                phosphatidylserine-binding;
FT                                dbSNP:1801690).
FT                                /FTId=VAR_008171.
FT   CONFLICT    121    121       S -> C (IN REF. 8).
FT   CONFLICT    188    188       C -> N (IN REF. 8).
FT   STRAND       23     24
FT   TURN         30     31
FT   STRAND       32     35
FT   STRAND       40     41
FT   TURN         43     44
FT   STRAND       46     51
FT   TURN         53     54
FT   STRAND       55     57
FT   TURN         58     59
FT   STRAND       62     65
FT   TURN         68     69
FT   STRAND       79     81
FT   STRAND       83     83
FT   TURN         91     92
FT   STRAND       93     96
FT   STRAND      101    101
FT   TURN        102    103
FT   STRAND      105    110
FT   TURN        112    113
FT   STRAND      114    117
FT   STRAND      121    124
FT   TURN        126    127
FT   STRAND      130    131
FT   STRAND      136    139
FT   STRAND      141    142
FT   TURN        149    150
FT   STRAND      151    155
FT   STRAND      160    160
FT   TURN        161    162
FT   STRAND      163    165
FT   TURN        166    167
FT   STRAND      169    174
FT   TURN        176    177
FT   STRAND      178    181
FT   STRAND      185    188
FT   TURN        190    191
FT   STRAND      194    194
FT   STRAND      199    202
FT   STRAND      204    205
FT   TURN        212    213
FT   STRAND      214    217
FT   STRAND      224    225
FT   TURN        226    227
FT   STRAND      229    234
FT   TURN        236    237
FT   STRAND      238    240
FT   STRAND      245    248
FT   TURN        250    251
FT   STRAND      254    254
FT   STRAND      260    262
FT   STRAND      264    264
FT   STRAND      272    274
FT   STRAND      279    281
FT   HELIX       282    285
FT   TURN        286    288
FT   STRAND      290    290
FT   TURN        292    293
```

```
FT   STRAND       295     302
FT   TURN         303     306
FT   STRAND       307     314
FT   STRAND       316     316
FT   TURN         317     318
FT   STRAND       319     319
FT   TURN         324     325
SQ   SEQUENCE   345 AA;  38298 MW;  63101704F8EDFE3F CRC64;

  P02749  Length: 345  March 12, 2004 11:34  Type: P  Check: 2134  ..

       1  MISPVLILFS SFLCHVAIAG RTCPKPDDLP FSTVVPLKTF YEPGEEITYS

      51  CKPGYVSRGG MRKFICPLTG LWPINTLKCT PRVCPFAGIL ENGAVRYTTF

     101  EYPNTISFSC NTGFYLNGAD SAKCTEEGKW SPELPVCAPI ICPPPSIPTF

     151  ATLRVYKPSA GNNSLYRDTA VFECLPQHAM FGNDTITCTT HGNWTKLPEC

     201  REVKCPFPSR PDNGFVNYPA KPTLYYKDKA TFGCHDGYSL DGPEEIECTK

     251  LGNWSAMPSC KASCKVPVKK ATVVYQGERV KIQEKFKNGM LHGDKVSFFC

     301  KNKEKKCSYT EDAQCIDGTI EVPKCFKEHS SLAFWKTDAS DVKPC
```